Royalty Pharma plc
RPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $609,291 | $578,665 | $568,247 | $593,641 |
| % Growth | 5.3% | 1.8% | -4.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $609,291 | $578,665 | $568,247 | $593,641 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $50,500 | $300,500 | $50,500 | $500 |
| G&A Expenses | $118,734 | $179,769 | $110,705 | $67,591 |
| SG&A Expenses | $118,734 | $179,769 | $110,705 | $67,591 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12,901 | -$111,403 | -$127,140 | $164,036 |
| Operating Expenses | $182,135 | $368,866 | $34,065 | $232,127 |
| Operating Income | $427,156 | $209,799 | $534,182 | $361,514 |
| % Margin | 70.1% | 36.3% | 94% | 60.9% |
| Other Income/Exp. Net | $17,055 | -$119,164 | -$100,749 | -$27,163 |
| Pre-Tax Income | $444,211 | $90,635 | $433,433 | $334,351 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $288,217 | $30,176 | $238,349 | $208,214 |
| % Margin | 47.3% | 5.2% | 41.9% | 35.1% |
| EPS | 0.667 | 0.071 | 0.547 | 0.468 |
| % Growth | 837.2% | -87% | 17.1% | – |
| EPS Diluted | 0.665 | 0.071 | 0.545 | 0.467 |
| Weighted Avg Shares Out | 431,887 | 432,288 | 425,590 | 445,985 |
| Weighted Avg Shares Out Dil | 559,611 | 562,000 | 578,000 | 589,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,903 | $8,327 | $11,290 | $9,037 |
| Interest Expense | $79,564 | $68,668 | $65,261 | $65,761 |
| Depreciation & Amortization | $1,277 | $0 | $0 | $0 |
| EBITDA | $525,052 | $159,303 | $498,694 | $400,112 |
| % Margin | 86.2% | 27.5% | 87.8% | 67.4% |